Discontinued — last reported Q3 '23
Viatris Other — Charges decreased by 33.3% to $200.00K in Q3 2023 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
An increase in these charges often indicates higher restructuring costs, legal settlements, or corporate overhead, which may negatively impact net income. A decrease suggests lower non-operational friction and potentially improved cost management.
This metric represents non-recurring or miscellaneous expenses allocated to the 'Other' business segment, which typicall...
Peers in the pharmaceutical industry often report similar items under 'unallocated corporate expenses' or 'restructuring and impairment charges', though the specific composition of 'Other' varies significantly by company structure.
vtrs_segment_other_charges| Q2 '23 | Q3 '23 | |
|---|---|---|
| Value | $300.00K | $200.00K |
| QoQ Change | — | -33.3% |